Cognition Therapeutics, Inc. (CGTX) Stock

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of small molecule therapeutics aimed at addressing age-related degenerative diseases and central nervous system disorders, as well as retinal conditions. Founded in 2007 and based in Purchase, New York, the company focuses on advancing innovative treatments to combat diseases such as Alzheimer's disease, dementia with Lewy bodies (DLB), Parkinson's disease, and dry age-related macular degeneration (AMD).

One of Cognition Therapeutics' primary initiatives revolves around CT1812, its leading product candidate. CT1812, a sigma-2 receptor antagonist, is currently undergoing Phase II clinical trials for mild-to-moderate Alzheimer's disease and dementia with Lewy bodies. The compound has also completed Phase I clinical trials for early-stage Alzheimer's disease and is being investigated in preclinical trials for dry AMD. Additionally, the company is advancing CT2168 for synucleinopathies, which encompass DLB and Parkinson's disease, and CT2074 for the treatment of dry AMD.

With a commitment to scientific innovation and therapeutic advancement, Cognition Therapeutics strives to meet the urgent medical needs posed by neurodegenerative diseases and retinal disorders. By leveraging its expertise in small molecule drug development and receptor-targeted therapies, the company aims to deliver transformative treatments that improve the quality of life for patients worldwide.

Headquartered in Purchase, New York, Cognition Therapeutics, Inc. continues to expand its pipeline and clinical research efforts, driven by a mission to develop novel therapies that address the complex challenges associated with aging-related neurological and retinal conditions. The company remains dedicated to pushing the boundaries of scientific discovery in pursuit of effective treatments for debilitating diseases that affect millions of individuals globally.